Reference-based pricing of prescription drugs: Exploring the equivalence of angiotensin-converting-enzyme inhibitors

CMAJ. Canadian Medical Association Journal

Volumn 161, Issue 3, 1999, Pages 255-260

  Bourgault, Chantal ^a,b   Elstein, Eleanor ^b   Le Lorier, Jacques ^c   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL;

ADULT; AGED; ARTICLE; CANADA; COST CONTROL; DATA BASE; DRUG COST; FEMALE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POLICY; PRESCRIPTION; REFERENCE VALUE; STATISTICS;

EID: 0033543069     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. National health expenditures in Canada 1975-1996. Ottawa: Health System and Policy Division, Health Canada; 1997. Cat no H21-99/1996.
2. McLaughlin PR. Reference-based pricing of prescription drugs. Can J Cardiol 1997;13:31-2.
3. Woollard RF. Opportunity lost: a frontline view of reference-based pricing [editorial]. CMAJ 1996;154(8):1185-8.
4. Strom BL. Generic drug substitution revisited. N Engl J Med 1987;316;1456-62.
5. Kaplan NM. Clinical hypertension. 7th ed, Baltimore: Williams & Wilkins; 1998.
6. McGregor M. Coverage of drug costs: reference-based pricing. Can J Cardiol 1998;14:666-8.
7. Rigter H. Recent public policies in the Netherlands to control pharmaceutical pricing and reimbursement. Pharmacoeconomics 1994;6(Suppl 1):15-21.
8. Canadian Cardiovascular Society. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Can J Cardiol 1997;13:33-45.
9. MacLeod SM. Improving physician prescribing practices: bridge over troubled waters [editorial]. CMAJ 1996;154(5):675-7.
10. Rubin RJ, Mendelson DN. A framework for cost-sharing policy analysis. Pharmacoeconomics 1996;10:56-67.
11. Boulet AP, Tessier G. Reference-based pricing in British Columbia: implications for cardiologists. An analysis. Can J Cardiol 1997;13:46-51.
12. Olley PM, McLaughlin PR. The Canadian Cardiovascular Society and reference-based drug pricing. Can J Cardiol 1998;14:669-70.
13. Rush JE, Merrill DD. The safety and tolerability of lisinopril in clinical trials. J Cardiovasc Pharmacol 1987;9(3 Suppl):S99-107.
14. Inman WH, Rawson NS, Wilton LV, Pearce GL, Speirs CJ. Postmarketing surveillance of enalapril. I: Results of prescription-event monitoring. BMJ 1988;297:826-9.
15. Herpin D, Conte D. Assessment of the antihypertensive effect of lisinopril using 24-hour ambulatory monitoring. J Hum Hypertens 1989;3(Suppl 1):11-5.
16. Rush JE, Lyle PA. Safety and tolerability of lisinopril in older hypertensive patients. Am J Med 1988;85:55-9.
17. Murray NH. Duration of angiotensin-converting-enzyme inhibition: implications for tolerability. Cardiology 1991;79(Suppl 1):22-9.
18. Espinel CH, Williams JL, Coughlin SS. Enalapril and lisinopril in the treatment of mild to moderate essential hypertension. Clin Ther 1990;12:181-90.
19. Moyses C, Higgins TJ. Safety of long term use of lisinopril for congestive heart failure. Am J Cardiol 1992;70:91C-97C.
20. Parish RC, Miller LJ. Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Surg 1992;7:14-31.
21. Howes LG. Critical assessment of ACE inhibitors. Part 2. Aust Fam Physician 1995;24:641-3.
22. Jenkins AC, Dreslinski GR, Tadros SS, Groel JT, Fand R, Herczeg SA. Captopril in hypertension: seven years later. J Cardiovasc Pharmacol 1985;7:S96-101.
23. Waeber B, Gavras I, Brunner HR, Gavras H. Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update. J Clin Pharmacol 1981;21:508-16.
24. Wiser T, Young LY. Essential hypertension. In: Young LY, Koda-Kimble M, editors. Applied therapeutics. The clinical use of drugs. 4th ed. Vancouver: Applied Therapeutics; 1988. p. 123-59.
25. McAreavey D, Robertson JL. Angiotensin-converting-enzyme inhibitors and moderate hypertension. Drugs 1990;40:326-45.
26. Gavras H, Gavras I. Angiotensin-converting-enzyme inhibitors. Properties and side effects. Hypertension 1988;11:II37-II41.
27. Gerbrandt KR, Yedinak KC. Formulary management of ACE inhibitors. Pharmacoeconomics 1996;10:594-613.
28. Lancaster SG, Todd PA. Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 1988;35:646-69.
29. Edwards CR, Padfield PL. Angiotensin converting-enzyme inhibitors: past, present and bright future. Lancet 1985;1:30-4.
30. Riley LJ Jr, Vlasses PH, Ferguson RK. Clinical pharmacology and therapeutic applications of the new oral converting enzyme inhibitor, enalapril. Am Heart J 1985;109:1085-9.
31. Irvin JD, Viau JM. Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril. Am J Med 1986;(Suppl 4C):46-50.
32. Case DB. Angiotensin-converting-enzyme inhibitors: Are they all alike? J Clin Hypertens 1987;3:243-56.
33. Gavras I, Gavras H. Captopril and enalapril. Ann Intern Med 1983;88:556-7.
34. Rotmensch HH, Vlasses PH, Ferguson RK. Resolutiun of captopril-induced rash after substitution of enalapril. Pharmacotherapy 1983;3:131-3.
35. Conway J, Coats AJ, Bird R. Lisinopril and enalapril in hypertension: a comparative study using ambulatory monitoring. J Hum Hypertens 1990;4:235-9.
36. Gosse P, Dallocchio M, Gourgon R. ACE inhibitors in mild to moderate hypertension: comparison of lisinopril and captopril administered once daily. French Cooperative Study Group. J Hum Hypertens 1989;3:23-8.
37. Gourlay S, McNeil J, Forbes A, McGrath B. Differences in the acute and chronic antihypertensive effects of lisinopril and enalapril assessed by ambulatory blood pressure monitoring. Clin Exp Hypertens 1993;15:71-89.
38. Plotquin Y, Barmat R, Bolanos R, Kirszner T, Saggese O, Bedrossian P, et al. Comparative study of the efficacy and duration of action of enalapril and lisinopril using 48-hour ambulatory blood pressure monitoring in patients with mild to moderate hypertension. Acta Therapeutica 1993;19:229-40.
39. Siche JP, de Gaudemarie R, De Lorraine A, Jalbert M, Mansour P, Madonna O, et al. Comparative trial of lisinopril and captopril (once daily) in mild to moderate essential hypertension: benefit of 24-hour ambulatory blood pressure monitoring. In: Keane WF, editor. A focus on the clinical effects of a lung acting ACE inhibitor / Hypertension. New York: Raven Press; 1990. p. 31-9.
40. Whelton A, Miller WE, Dunne B Jr, Hait HI, Tresznewsky ON. Once-daily lisinopril compared with twice-daily captopril in the treatment of mild to moderate hypertension: assessment of office and ambulatory blood pressures. J Clin Pharmacol 1990;30:1074-80.
41. Whelton A, Dunne B Jr, Glazer N, Kostis JB, Miller WE, Rector DJ, et al. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension. J Hum Hypertens 1992;6:325-31.
42. West R. Saskatchewan health databases: a developing resource. Am J Prev Med 1987;4(Suppl 2):25-7.
43. Strand LM, Downey W. Health databases in Saskatchewan. In; Strom B, editor. Pharmacoepidemiology. 2nd ed. Chichester (UK): John Wiley & Sons; 1994. p. 217-29.
44. Rawson N. Aspects of the validity of the Saskatchewan administrative health care utilization datafiles [abstract]. Pharmacoepidemiol Drug Saf 1994;3(Suppl 1):S3.
45. Malcolm E, Downey W, Strand LM, McNutt M, West R. Saskatchewan Health's linkable databases and pharmacoepidemiology. Post Market Surveil 1993;6:175-264.
46. World Health Organization. Manual of the international statistical classification of diseases, injuries and causes of death. 9th ed rev. Geneva: The Organization; 1977.
47. McCullagh P, Nelder JA. Generalized linear models. 2nd ed. Monograph on statistics and applied probability 37. London (UK): Chapman and Hall; 1989.
48. Reeder CE, Lingle EW, Schultz RM, Mauch RP Jr, Nightengale BS, Pedersen CA, et al. Economic impact of cost-containment strategies in Third Party Programmes in the US (Part I). Pharmacoeconomics 1993;4:92-103.
49. Kozma CM, Schulz RM, Dickson WM, Dye JT, Cox ER, Holdford DA, et al. Economic impact of cost-containment strategies in Third Party Programmes in the US (Part II). Pharmacoeconomics 1993;4:187-202.
50. Briscoe TA, Dearing CJ. Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients. Am J Health Syst Pharm 1996;53:2191-3.
51. Gill TH, Hauter F, Pelter MA. Conversions from captopril to lisinopril at a dosage ratio of 5:1 result in comparable control of hypertension. Ann Pharmacother 1996;30:7-11.
52. Hilleman DE, Mohiuddin SM, Wurdeman RL, Wadibia EC. Outcomes and cost savings of an ACE inhibitor therapeutic interchange. J Man Care Pharm 1997;3:219-23.
53. Borden EK. Pharmacoepidemiology in Canada in the '90s - Where is the role in treatment decision-making? Can J Clin Pharmacol 1996;3:165-6.
54. Strom BL, Melmon KL. The use of pharmacoepidemiology to study beneficial drug effects. In: Strom B, editor. Pharmacoepidemiology 2nd ed. Chichester (UK): John Wiley & Sons; 1994. p. 449-67.
55. Strom BL, Miettinen OS, Melmon KL. Postmarketing studies of drug efficacy: When must they be randomized? Clin Pharmacol Ther 1983;34:1-7.